Whitepaper/App Note

Scientific Poster: Quantitation of monoclonal antibody infliximab in human plasma by LC-MS/MS using Fab-selective limited proteolysis nSMOL technology

Posted: 6 September 2018 | | No comments yet

Infliximab, commercially known as Remicade, is a chimeric IgG1 kappa monoclonal antibody (mAb), that targets tumor necrosis factor-alpha (TNF)….

However, a number of studies have identified a substantial proportion of patients (between 30‑40%) who fail to respond to anti-TNF therapy. Current methods for monitoring infliximab are almost exclusively immunoassay based. In this study, we describe the use of nSMOL proteolysis, which selectively targets the Fab CDR region of infliximab, and LC-MS/MS quantitation.

The rest of this Scientific Poster is restricted - login or subscribe free to access

european pharmaceutical review 4 2018Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • bi-monthly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here

 

Send this to a friend